title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Limitations | Our study has several limitations. The Camden Core Model did not establish a priori criteria to define full intervention exposure at the time of trial implementation. We used a combination of data distributions and guidance from program designers to select the engagement definition used for this analysis and tested sev... | PMC10498327 | ||
Conclusions | The conclusion from the original randomized clinical trial of the Camden Core Model that the intervention did not work may have been premature, because the estimated treatment effect in the ITT analysis was averaged over a population including patients who received low-intensity and short-term intervention. In this rea... | PMC10498327 | ||
Objective | Cushing’s disease | POLAND | Edited by: Renato Cozzi, Endocrinology Unit Ospedale Niguarda, ItalyReviewed by: Przemyslaw Witek, Warsaw Medical University, Poland; Athanasios Fountas, General Hospital of Athens G. Genimatas, Greece†Present addresses: Alberto M. Pedroncelli, Chief Medical Office, Camurus AB, Lund, SwedenRicardo Maamari, Global Medic... | PMC10593462 |
Study design | This is an open-label, multicenter, non-comparative, Phase II study comprising 35-week core phase and an optional extension phase. All patients started with pasireotide, and cabergoline was added if cortisol remained elevated. Eligible patients had active CD, with or without prior surgery, were pasireotide naïve at scr... | PMC10593462 | ||
Results | Hyperglycemia, nausea, diarrhea, cholelithiasis, hypercortisolism | ADVERSE EVENTS, HYPERGLYCEMIA, HYPERCORTISOLISM, CHOLELITHIASIS | Of 68 patients enrolled, 26 (38.2%) received pasireotide monotherapy and 42 (61.8%) received pasireotide plus cabergoline during the core phase. Thirty-four patients (50.0%; 95% CI 37.6–62.4) achieved the primary endpoint, of whom 17 (50.0%) received pasireotide monotherapy and 17 (50.0%) received combination therapy. ... | PMC10593462 |
Conclusion | hypercortisolism | HYPERCORTISOLISM | Addition of cabergoline in patients with persistently elevated mUFC on maximum tolerated doses of pasireotide is an effective and well-tolerated long-term strategy for enhancing control of hypercortisolism in some CD patients. | PMC10593462 |
Clinical trial registration | PMC10593462 | |||
Introduction | pituitary tumor, Cushing’s disease | PITUITARY TUMOR, SECONDARY, OVERPRODUCTION OF CORTISOL | Cushing’s disease (CD) is a rare condition arising from chronic overproduction of cortisol, secondary to an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor (Pasireotide is a second-generation, multireceptor-targeted somatostatin receptor ligand (SRLs), with affinity for 4 of the 5 known somatostatin recept... | PMC10593462 |
Materials and methods | PMC10593462 | |||
Patients | Adults (≥18 years) with a confirmed diagnosis of CD or | PMC10593462 | ||
Study design | This was a single-arm, open-label, multicenter, non-comparative, Phase II study. After 4 weeks of screening, patients were treated in a stepwise approach during the core phase. Patients received subcutaneous pasireotide 0.6 mg twice daily (bid) for 8 weeks. Patients with a mUFC level exceeding ULN after 8 weeks receive... | PMC10593462 | ||
End points and assessments | hirsutism | HIRSUTISM | The primary endpoint of the study was the proportion of patients with mUFC ≤ULN at week 35. Secondary endpoints (reported at 4-week intervals up to week 35 and 8-week intervals from week 43 to the date of the last patient visit) included changes from baseline in mUFC, plasma ACTH, serum cortisol, total cholesterol, and... | PMC10593462 |
Statistical analyses | No formal hypothesis testing was performed because of the exploratory design of the study. Efficacy analyses were conducted on full analysis set, i.e., all patients to whom study treatment was assigned. Safety analyses were conducted on all patients who received ≥1 dose of pasireotide per day during the study. For pati... | PMC10593462 | ||
Results | PMC10593462 | |||
Study population | ADVERSE EVENTS, RECURRENT DISEASE | A total of 68 patients were enrolled in the study. At baseline, 66 (97.1%) patients were pasireotide naïve, while 2 (2.9%) were treated with pasireotide previously with 4 weeks of washout period prior to screening (Patient demographics and baseline characteristics.*Persistent or recurrent disease refers to patients wit... | PMC10593462 | |
Efficacy: biochemical response | hypercortisolism | HYPERCORTISOLISM | Overall, 34/68 (50.0%; 95% CI 37.6–62.4) patients achieved the primary endpoint, of whom 17 (50.0%) were receiving pasireotide monotherapy and 17 (50.0%) were receiving combination therapy. Patients with mild hypercortisolism (mUFC 1.0–<2.0 x ULN) at baseline were more likely to respond to both pasireotide monotherapy ... | PMC10593462 |
Clinical signs and symptoms of CD | Relative to baseline, pasireotide monotherapy was accompanied by reductions in median blood pressure, weight, BMI, waist circumference, and total cholesterol. Overall improvement in clinical measures persisted over time (Mean( ± SD) standardized CushingQoL score was 41.6(± 20.2) at baseline and increased to 47.6(± 20.8... | PMC10593462 | ||
Safety and tolerability | Hyperglycemia, death, multi-organ dysfunction, hyperglycemia, hyperglycemia-related AEs, deaths | HYPERGLYCEMIA, UNCONTROLLED HYPERTENSION, ADVERSE EVENTS, HYPERGLYCEMIA, ADVERSE EVENT, SYNDROME | Median duration of exposure to pasireotide was 35.0 weeks (range 0−;268), with a median dose of 1.53 mg/day (range 0.29−;1.80). Median duration of exposure to cabergoline was 16.9 weeks (range 1−;215), with a median dose of 0.50 mg/day (range 0.44−;0.97).All patients (N=68) reported at least one AE and 28/68 (41.2%) pa... | PMC10593462 |
Discussion | pituitary tumor, tumor, mild/moderate, hypercortisolemia, hypercortisolism | PITUITARY TUMOR, TUMOR, DISEASE, HYPERCORTISOLEMIA, HYPERCORTISOLISM | The severe morbidity and increased mortality with uncontrolled CD highlight the importance of identifying an effective medical strategy. This study explored the potential of a synergistic benefit of the addition of cabergoline to pasireotide treatment in patients with CD.Complete normalization of cortisol production is... | PMC10593462 |
Conclusions | This is the first study demonstrating that pituitary-targeted combination treatment with pasireotide and cabergoline doubled the number of patients who attained mUFC ≤ULN. Both short- and long-term safety profile are consistent with known data for pasireotide and cabergoline. The low rate of discontinuation due to AEs ... | PMC10593462 | ||
Data availability statement | The original contributions presented in the study are included in the article/ | PMC10593462 | ||
Ethics statement | Ethische | DELHI | The studies involving humans were approved by Hospital Britanico, Buenos Aires, Argentina; Ethische commissie University Hospitals Leuven, Leuven, Belgium; Universitair Ziekenhuis Gent, Gent, Belgium; Comite de Etica em Pesquisa Hospital Moinhos de Vento, Porto Alegre-RS, Brazil; Comitê de Ética em Pesquisa do Hospital... | PMC10593462 |
Author contributions | All authors directly participated in the planning, execution, or analysis, and have had full control of complete primary data, and hold responsibility for data integrity and accuracy. All authors contributed to the article and approved the submitted version. | PMC10593462 | ||
Acknowledgments | BROWN | We thank Julie Brown, Mudskipper Business Ltd, and Manojkumar Patel and Sashi Kiran Goteti, Novartis Healthcare Private Limited, for medical editorial assistance with this manuscript. We would also like to thank all investigators, sub-investigators, study nurses and coordinators, and patients who have made this study p... | PMC10593462 | |
Conflict of interest | Neuroendocrine CAH, RP | OSTEOPOROSIS, RARE DISEASE | HP and RM were Novartis employees and owned Novartis stocks. AMP was employed by Novartis and Recordati. AC is a Novartis employee and owns Novartis stocks. RF received research grants from Strongbridge and Corcept, consulting fee from Recordati, honoraria and financial support for meetings and/or travel from HRA Pharm... | PMC10593462 |
Publisher’s note | All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or ... | PMC10593462 | ||
Supplementary material | The Supplementary Material for this article can be found online at: Click here for additional data file. | PMC10593462 | ||
References | PMC10593462 | |||
Background: | RECRUITMENT, ACUTE RESPIRATORY DISTRESS SYNDROME, POSITIVE | Positive end-expiratory pressure (PEEP) benefits in acute respiratory distress syndrome are driven by lung dynamic strain reduction. This depends on the variable extent of alveolar recruitment. The recruitment-to-inflation ratio estimates recruitability across a 10–cm H | PMC10723770 | |
Methods: | COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME | Twenty patients with moderate-to-severe COVID-19 acute respiratory distress syndrome underwent a decremental PEEP trial (PEEP 15 to 13 to 10 to 8 to 5 cm H | PMC10723770 | |
Results: | Between 15 and 5 cm H | PMC10723770 | ||
Conclusions: | COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME | Both global and granular recruitment-to-inflation ratio accurately estimate PEEP-induced changes in lung dynamic strain. However, the effect of 10 cm HIn a cohort of patients with moderate to severe COVID-19 acute respiratory distress syndrome, the authors determined respiratory mechanics and end-expiratory lung volume... | PMC10723770 | |
Visual Abstract: | PMC10723770 | |||
Editor’s Perspective | PMC10723770 | |||
What We Already Know about This Topic | acute respiratory distress syndrome, baby lung overinflation | RECRUITMENT, ACUTE RESPIRATORY DISTRESS SYNDROME | The ability to determine the optimal positive end-expiratory pressure (PEEP) for patients with acute respiratory distress syndrome may have important clinical ramifications.The optimal PEEP in such patients aims at reducing lung dynamic strain while avoiding baby lung overinflation. The balance between these two effect... | PMC10723770 |
What This Article Tells Us That Is New | ventilator-induced lung injury, ARDS | COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME, ARDS, RECRUITMENT, ACUTE RESPIRATORY DISTRESS SYNDROME | In a cohort of patients with moderate to severe COVID-19 acute respiratory distress syndrome, the authors determined respiratory mechanics and end-expiratory lung volume by nitrogen dilution over a 10–cm HThe global effect displayed a linear correlation of both global and granular recruitment-to-inflation ratio with dy... | PMC10723770 |
Materials and Methods | This prospective, physiologic study was conducted in the intensive care unit (ICU) of a tertiary care university hospital between April and June 2021. Approval was obtained by local institutional review board, Comitato Etico Policlinico Gemelli. Written informed consent was obtained by patients’ legal representatives a... | PMC10723770 | ||
Patients | ARDS | ARDS | Consecutive patients admitted to the ICU between April and July 2021 and fulfilling moderate-to-severe ARDS criteria | PMC10723770 |
Procedures and Measurements | Neuromuscular blockade | NEUROMUSCULAR BLOCKADE | All patients were in the semirecumbent position (30° to 45° head-of-the-bed elevation) and sedated according to standard practice. Neuromuscular blockade was accomplished by cisatracurium continuous infusion at the dose of 35 mg · hStudy procedures are summarized in figure Flow chart of the study protocol. After assess... | PMC10723770 |
Alveolar Recruitment and PEEP-induced Inflation | PEEP-related total volume (PEEPvol) was computed as the difference between end-expiratory lung volume at higher PEEP (EELVVRecruited volume was then normalized to the change in PEEP (Crec = VRecruitment-to-inflation ratio = Crec/CrsThe same parameters were also computed across the whole tested PEEP range by using 15 cm... | PMC10723770 | ||
Strain Indices. | RECRUITMENT | Aerated lung volume (FRC + recruitment) at each PEEP level was calculated as the sum of FRC (After the study end, ventilation was resumed as clinically indicated by the attending physician.Of note, although physiologic measurements were derived from derecruitment PEEP trials, we refer to the terms “recruitment” and “re... | PMC10723770 | |
Endpoints | Study endpoints were (1) to assess the behavior of the recruitment-to-inflation ratio across the traditionally tested 15 to 5 cm H | PMC10723770 | ||
Sample Size Calculation and Statistical Analysis | Given the physiologic design of the study, consistent with previous investigations with similar design on the topic,Continuous data are expressed as median [interquartile range], and dichotomous variables are displayed as frequencies (%). Paired comparisons between study steps were performed with the Wilcoxon rank sum ... | PMC10723770 | ||
Mathematical Modeling | RECRUITMENT | As an exploratory analysis, recruitment-to-inflation ratio values obtained in each derecruitment step were regressed (by nonlinear ordinary least-squares) against average step PEEP with a quadratic (parabolic) model, constrained to pass through the point (0,0), assuming essentially no recruitment at extremely low PEEP ... | PMC10723770 | |
Results | ARDS | ARDS, POSITIVE | Twenty-six patients were screened for enrollment. Six patients (23%) showed intrinsic PEEP or airway closure with airway opening pressure greater than 5 cm HTwenty COVID-19 ARDS patients were studied. Demographics and clinical characteristics at enrollment are displayed in Supplementary table 1 (The median PaStudy vari... | PMC10723770 |
Potential for Lung Recruitment | Between PEEP 5 and 15 cm HCrec and recruitment-to-inflation ratio in the four PEEP ranges along with global Crec and recruitment-to-inflation ratio measured between PEEP 15 and 5 cm H(Average recruitment-to-inflation ratio measured in the four narrow PEEP ranges (median, 1.11 [0.38 to 1.52]) was highly correlated (r = ... | PMC10723770 | ||
Respiratory Mechanics and Lung Strain | As compared to PEEP 5 cm HAs expected, dynamic strain at PEEP 15 cm H | PMC10723770 | ||
Lung Strain Indices | RECRUITMENT | Respiratory system compliance and aerated lung volume (FRC + recruitment) were linearly correlated at PEEP 5 cm HThe reduction dynamic and total strain and the increase in static strain produced by the 10–cm HRelationship between the PEEP-induced percent change in dynamic strain, static strain, and total strain, and th... | PMC10723770 | |
Discussion | lung injury, derecruitment, ventilator-induced lung injury, ARDS | LUNG HYPERINFLATION, ARDS, RECRUITMENT | The results of the current physiologic study conducted on patients with early moderate-to-severe COVID-19 ARDS can be summarized as follows:Recruitment-to-inflation ratio calculated between 15 and 5 cm HRespiratory mechanics changes induced by PEEP are ineffective estimates of the changes produced on lung strain (Suppl... | PMC10723770 |
Conclusions | Recruitment-to-inflation ratio assessed by reducing PEEP from 15 to 5 cm H | PMC10723770 | ||
Research Support | Support was provided solely from institutional and/or departmental sources. | PMC10723770 | ||
Competing Interests | Dr. Grieco has received payments for travel expenses from Getinge (Göteborg, Sweden), and personal fees from GE Healthcare (Chicago, Illinois), Intersurgical (Mirandola, Italy), Fisher & Paykel Healthcare (Auckland, New Zealand), and Merck Sharp & Dohme (Rahway, New Jersey). Dr. Maggiore is the principal investigator o... | PMC10723770 | ||
Supplemental Digital Content | Supplementary Figure 1: Relationship between aerated lung size and respiratory system compliance and dynamic strain and driving pressure measured at low (Supplementary Figure 2: Respiratory system compliance, driving pressure, and PaSupplementary Table 1: Demographics and baseline characteristics of enrolled patients. ... | PMC10723770 | ||
Supplementary Material | The article processing charge was funded through the authors’ institution.This article is featured in “This Month in Anesthesiology,” page A1.This article is accompanied by an editorial on p. 719.Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are availabl... | PMC10723770 | ||
References | PMC10723770 | |||
1. Introduction | muscle mass, deaths | VIRUS | The COVID-19 pandemic limited older adults’ access to preventative and diagnostic services and negatively affected accessibility to age-appropriate exercise programs. The purpose of this study was to assess the feasibility of conducting guided virtual functional fitness assessments before and after participation in an ... | PMC10252352 |
2. Materials and Methods | PMC10252352 | |||
2.1. Participant Recruitment and Enrollment | RECRUITMENT | Approval for human subjects research was obtained by the Institutional Review Board of the lead researcher’s university prior to the study. A recruitment flyer was distributed to members of a membership-based village organization that assists older adults in maintaining independent living. Inclusion criteria included b... | PMC10252352 | |
2.2. In-Person Assessment Process | STAGGERED | Participants were scheduled for a 60 min assessment appointment in a multi-purpose room in a community center where the research team delivered all assessments following standardized communication scripts. Prior to the assessment appointment, the room was arranged for testing with consistent room temperature and lighti... | PMC10252352 | |
2.3. Virtual Assessment Process | CREST, STAGGERED | Participants were virtually assessed via Zoom by different members of the research team than those who completed the in-person assessments in the same order that assessments were completed in the in-person format. Height and weight were not measured virtually. Researchers utilized the same commonly used, validated asse... | PMC10252352 | |
2.4. Implementation of the Virtual Fitness Training Program | The virtual fitness training program was delivered by Vivo (The 8-week fitness program consisted of two 45 min sessions per week. Sessions were delivered via Zoom. Each session consisted of a 15 min warm up involving cognitive dual tasks, dynamic mobility exercises for the ankle, hip, spine, and shoulders, and balance ... | PMC10252352 | ||
2.5. Assessment of Exercise Fidelity | Fitness training program fidelity was monitored via four live or recorded exercise sessions. Researchers evaluated the class elements based on an observation checklist in order to assess the effectiveness of program delivery of each of the trainers. Fidelity checks included critiques of the trainers’ level of preparedn... | PMC10252352 | ||
2.6. Statistical Analysis | Descriptive statistics were calculated to summarize all dependent variables and two-tail dependent t-tests were conducted to determine if differences existed between in-person and virtual assessment variables. Additionally, one-tailed dependent t-tests were performed to determine if differences existed between pre-test... | PMC10252352 | ||
3. Results | PMC10252352 | |||
In-Person and Virtual Functional Fitness Assessments | In-person and virtual functional fitness assessment measures for both pre- and post-test are shown in Significant differences were found in several of the in-person functional fitness assessments when comparing pre-test to post-test timepoints. Both lower and upper-body strength improved as measured by the 30 s Chair S... | PMC10252352 | ||
4. Discussion | anxiety | ADVERSE EVENTS | Functional fitness measures are commonly used in clinical and research settings to determine one’s functional abilities. With COVID-19 and the need to socially distance and isolate, alternative ways to conduct these measurements were necessary, as coming into a clinic or a research facility may not have been an option.... | PMC10252352 |
5. Conclusions | The COVID-19 pandemic provided an opportunity to determine the feasibility of utilizing virtual functional fitness assessments when in-person functional fitness assessments were not an option. This study successfully delivered virtual functional fitness assessments, showing no difference between them and the in-person ... | PMC10252352 | ||
Author Contributions | Conceptualization, C.T., K.N.P.S. and E.C.K.; methodology, C.T.; software, C.T., J.C., E.J. and J.P.; validation, C.T., J.C, E.J. and J.P.; formal analysis, C.T., J.C., E.J. and J.P.; writing—original draft preparation, C.T., J.C., E.J. and J.P.; writing—review and editing, K.N.P.S. and E.C.K.; funding acquisition, C.T... | PMC10252352 | ||
Institutional Review Board Statement | The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of University of San Francisco (protocol code 1790, 7 August 2023). | PMC10252352 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10252352 | ||
Data Availability Statement | Data and data analyses are available and may be reviewed by following this Google Drive link and then requesting access by contacting Christian Thompson at | PMC10252352 | ||
Conflicts of Interest | Thompson and Starr are scientific advisors for Vivo and Kemp is an employee of Vivo, and they were in these roles at the time of research and analysis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflic... | PMC10252352 | ||
References | Functional fitness assessment measures.In-person and virtual assessment descriptive statistics for all subjects (n = 13).Note: * indicates significant difference (≤0.05) between pre-test and post-test measurements. | PMC10252352 | ||
Background | hypotensive, Postoperative cognitive dysfunction | HYPOTENSIVE, COMPLICATION | Postoperative cognitive dysfunction is a noteworthy complication of deliberate hypotensive anesthesia. The aim of this work was to compare the effect of deliberate hypotensive anesthesia using nitroglycerine versus phentolamine on event-related potentials and cognitive function in patients undergoing septoplasty surger... | PMC10155363 |
Methods | This prospective randomized controlled trial was conducted on 80 patients indicated for septoplasty under general anesthesia; 40 patients received intra-operative Nitroglycerine and 40 patients received intra-operative Phentolamine. Cognitive assessment (using Paired Associate Learning test (PALT) and Benton Visual Ret... | PMC10155363 | ||
Results | The scores of PALT and Benton BVRT significantly declined one week following surgery in both Nitroglycerine and Phentolamine groups. There was no statistically significant difference between Nitroglycerine and Phentolamine groups in the postoperative decline in either PALT or BVRT (P-value = 0.342, 0.662 respectively).... | PMC10155363 | ||
Conclusion | hypotensive | HYPOTENSIVE | Phentolamine is preferred over nitroglycerin in deliberate hypotensive anesthesia because it has less harmful effect on cognitive function than nitroglycerin. | PMC10155363 |
Keywords | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). | PMC10155363 | ||
Introduction | POCD, hypotensive, hypotension, Postoperative cognitive dysfunction | HYPOTENSIVE, VASODILATATION | Postoperative cognitive dysfunction (POCD) has gained much attention in the past years. Despite the great strides in anesthesia and surgical techniques over the past decades, POCD is still highly prevalent [Deliberate hypotensive anesthesia is necessary during maxillofacial and septoplasty surgery for drying surgical f... | PMC10155363 |
Methods | PMC10155363 | |||
Study design and population | MAY | This prospective randomized controlled trial was conducted on 80 patients indicated for septoplasty under general anesthesia. Patients were randomly assigned into one of two groups; the first group (40 patients) received intra-operative Nitroglycerine (Nitroglycerine group) and the second group (40 patients) received i... | PMC10155363 | |
Eligibility criteria | allergic, mean arterial blood pressure, hypotension, metabolic illness, hypotensive, visual or auditory dysfunction | HYPOTENSIVE, NEURODEGENERATIVE DISORDER | The study included American Society of Anesthesiologists I, II (ASA I, II) patients who were candidate for septoplasty. The age range was between 20 and 50 years. The following patients were excluded from the study: patients who developed intraoperative hypotension with mean arterial blood pressure (MAP) less than 60 m... | PMC10155363 |
Neurophysiological assessment | head movements | P300 recording was done for all included patients pre-operatively and one week postoperatively by an expert neurophysiologist who was blinded to the intraoperative drugs used. The used device was Galileo Series preamplifiers acquisition system (EBN, Florence, Italy). Bioelectrical activity of the brain was recorded by ... | PMC10155363 | |
Anesthetic technique | hypotensive, hypotension | HYPOTENSIVE, MUSCLE RELAXATION | At the operating room, standard patient monitoring was established (electrocardiography, pulse oximetry, end-tidal carbon dioxide (ET CO2 ), and noninvasive arterial blood pressure monitoring). Two intravenous cannulas were placed; 18 and 20 gauge.Induction of anesthesia was done by injecting 2 mg/kg propofol, 2 µg/kg ... | PMC10155363 |
Sampling | hypotensive | HYPOTENSIVE | Because our study was the first study to compare the effect of deliberate hypotensive anesthesia using nitroglycerine versus phentolamine on P300, we calculated the sample size based on the results of a pilot study we performed before starting our study. The sample size calculation was done using G*Power version 3.1.9.... | PMC10155363 |
Statistical analysis | IBM SPSS (Statistical Package of Social Science) Version 25 was used to analyze the data. Categorical variables such as sex were expressed as numbers and percentages. Quantitative variables such as age, years of education, PALT, BVRT, P300 latency, and amplitude were expressed as the median and interquartile range (IQR... | PMC10155363 | ||
Results | PMC10155363 | |||
Demographics, preoperative psychometric tests, and P300 latency and amplitude | Visual Retention | This prospective randomized controlled trial was conducted on 80 patients indicated for septoplasty under general anesthesia. Forty patients received intra-operative Nitroglycerine (Nitroglycerine group), and 40 patients received intra-operative Phentolamine (Phentolamine group). Consort flow diagram is illustrated in ... | PMC10155363 | |
Effect of nitroglycerine versus phentolamine on the scores of psychometric tests | Visual Retention, groups,*P-value ≤ | The scores of PALT significantly declined one week following surgery in both Nitroglycerine and Phentolamine groups (P-value = 0.034, 0.018 respectively). Also, the scores of BVRT significantly declined one week following surgery in both Nitroglycerine and Phentolamine groups (P-value = 0.013, 0.025 respectively). Ther... | PMC10155363 | |
Effect of nitroglycerine versus phentolamine on P300 latency and amplitude | groups,*P-value ≤ | The values of P300 latency showed a significant delay one week following surgery in both Nitroglycerine and Phentolamine groups (P-value ≤ 0.001, 0.001), but in Nitroglycerine group, the delay is significantly higher than in Phentolamine group (P-value = 0.003). The values of P300 amplitude significantly decreased one ... | PMC10155363 | |
Discussion | cerebrovascular insufficiency, neuroapoptosis, cerebral hypoperfusion, stroke, POCD, hypotensive, cognitive domain | CEREBROVASCULAR INSUFFICIENCY, NEURODEGENERATION, STROKE, BRAIN, HYPOTENSIVE, CORTEX | Since deliberate hypotensive anesthesia is appropriate for patients who will undergo certain surgical procedures, including septoplasty surgery[In the presence of contradictions in the results of previous studies, whether or not hypotensive anesthesia causes POCD [It is well-established that temporal lobe structures, e... | PMC10155363 |
Acknowledgements | Not applicable. | PMC10155363 | ||
Authors’ Contributions | MH, RS | WF participated in study design, collection and interpretation of data and helped to draft the manuscript. MH participated in study design, analysis and interpretation of data and helped to draft the manuscript. RM participated in study design, analysis and interpretation of data and helped to draft the manuscript. HS ... | PMC10155363 | |
Funding | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). | PMC10155363 | ||
Data Availability | Authors report that the datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. | PMC10155363 | ||
Declarations | Authors report that the content has not been published or submitted for publication elsewhere. | PMC10155363 | ||
Competing interests | Authors have no competing interest. | PMC10155363 | ||
Ethics approval and consent to participate | Written informed written consent was signed from all participants. The study was performed in agreement with the Declaration of Helsinki. Ethical approval for this study was obtained from the Research ethical committee of Beni-Suef University. The ethical committee approval number is FMBSUREC/31032019/HUSSEIN. | PMC10155363 | ||
Consent for publication | Not applicable. | PMC10155363 | ||
References | PMC10155363 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.